The goal of this study is to explore the trajectory patterns of chemotherapy induced peripheral neuropathy over the course of chemotherapy and identify predictors of distinct trajectories in children with acute lymphoblastic leukemia. A perspective longitudinal study design is utilized. Chemotherapy induced peripheral neuropathy was assessed at one week after the first use of Vincristine (VCR) (T1), one week after the second use of VCR (T2), one week after the third use of VCR (T3), one week after the fourth use of VCR (T4), two weeks after T4 (T5), two weeks after T5 (T6), two weeks after T5 (T7). Patients' demographic and clinical characteristics, physical symptoms, nutrition status, psychological distress, sleep quality, physical activity, perceived social support and coping strategy are obtained at baseline.
diagnosed with acute lymphoblastic leukemia
aged from 8 to 17 years
will receive vincristine according the Chinese Children's Cancer Group Acute Lymphoblastic Leukemia-2020 Project (CCCG-ALL-2020)
conscious with sufficient cognitive abilities to understand and express their physical state and psychological feelings accurately
participating other experimental trials, such as electrical stimulation, exercise therapy may improve CIPN symptoms.
with severe complications, including but not limited to significant heart, brain, or lung function failure.
had peripheral neuropathy symptoms caused by other diseases like genetic diseases, spinal cord injury.
had neuromuscular diseases (e.g., traumatic brain injury and cerebral palsy).